collection
MENU ▼
Read by QxMD icon Read
search

LUNG

shared collection
349 papers 100 to 500 followers
https://www.readbyqxmd.com/read/29268561/pulmonary-inflammatory-myofibroblastic-tumor-with-tpm4-alk-translocation
#1
Katsuhiro Okuda, Takuya Watanabe, Risa Oda, Tadashi Sakane, Osamu Kawano, Hiroshi Haneda, Satoru Moriyama, Ryoichi Nakanishi
A 35-year-old woman with shortness of breath and cough was referred to our hospital and agreed to receive therapy for lung tumor in our hospital. Based on the findings from a bronchoscopic biopsy, she was suspected of having pulmonary inflammatory myofibroblastic tumor (IMT), but a correct diagnosis was not indicated. Right upper wedge lobectomy was performed. The findings of a pathological examination of the permanent surgical resected tissue, the ultimate diagnosis was pulmonary IMT. The immunohistochemistry of ALK using the intercalated antibody-enhanced polymer (iAEP) method was positive...
November 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29299410/perspectives-in-small-cell-lung-cancer-is-something-moving
#2
EDITORIAL
Lucio Crinò, Angelo Delmonte
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29299413/raising-the-bar-the-future-of-egfr-inhibition-in-non-small-lung-cancer
#3
EDITORIAL
Amanda J Redig
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29299415/small-cell-lung-cancer-in-the-era-of-immunotherapy
#4
EDITORIAL
Margarita Majem, Charles M Rudin
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29205880/intrapulmonary-teratoma-misdiagnosed-as-aspergilloma
#5
Chuan Li, Feng Lin, Chengwu Liu, Yang Hai, Lunxu Liu
No abstract text is available yet for this article.
December 4, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29266865/survival-analysis-of-patients-with-advanced-non-small-cell-lung-cancer-receiving-tyrosine-kinase-inhibitor-tki-treatment-a-multi-center-retrospective-study
#6
Qingming Shi, Maojing Guan, Yong Wang, Congjing Xu, Lei Tang, Wenhua Fu, Minghong Bi, Xiang Sun, Kangsheng Gu, Dongsheng Pang
BACKGROUND: The study was conducted to assess differences in overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving different treatment modalities of tyrosine kinase inhibitors (TKIs). METHODS: A total of 463 NSCLC patients receiving TKI treatment were included. OS was compared according to treatment timing in all patients, the elderly, and patients positive for EGFR mutations. RESULTS: One hundred and seventy two patients received TKIs as first-line treatment, 220 as second-line, and 67 as third-line...
December 20, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29271588/pathological-diagnosis-of-pulmonary-large-cell-neuroendocrine-carcinoma-by-endobronchial-ultrasound-guided-transbronchial-needle-aspiration
#7
Terunaga Inage, Takahiro Nakajima, Taiki Fujiwara, Yuichi Sakairi, Hironobu Wada, Hidemi Suzuki, Takekazu Iwata, Masako Chiyo, Yukio Nakatani, Ichiro Yoshino
BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a relatively rare subtype of lung malignancy. According to revised 2015 World Health Organization (WHO) criteria for the pathological diagnosis of LCNEC, neuroendocrine markers must be examined by immunohistochemistry. In this study, we reevaluated endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples of patients previously diagnosed with LCNEC using the revised WHO criteria. METHODS: Clinical tissue samples that had been obtained by EBUS-TBNA between January 2004 and December 2011, and that had been pathologically diagnosed as LCNEC according to the previous criteria, were reevaluated according to the revised WHO criteria...
December 22, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29184671/urine-test-for-egfr-analysis-in-patients-with-non-small-cell-lung-cancer
#8
REVIEW
Aleksandra Franovic, Victoria M Raymond, Mark G Erlander, Karen L Reckamp
Precision medicine approaches in oncology are reliant on the accurate genomic characterization of tumors. While tissue remains the mainstay specimen for molecular testing, tumor biopsies are riddled with challenges and limitations due to their invasive and site-specific nature. Tumor inaccessibility and intratumoral heterogeneity, in particular, represent significant obstacles to the identification of actionable genetic alterations and hence effective mono- and combination therapy strategies. Proof-of-concept studies indicate that circulating tumor DNA (ctDNA) released from multiple tumor regions and anatomical locations is more reflective of intra- and intertumoral heterogeneity...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29196470/endobronchial-epithelial-myoepithelial-carcinoma-of-the-lung
#9
Chang Hoon Kim, Jae Seok Jeong, So Ri Kim, Yong Chul Lee
No abstract text is available yet for this article.
December 1, 2017: Thorax
https://www.readbyqxmd.com/read/29199595/epidermal-growth-factor-receptor-tyrosine-kinase-a-potential-target-in-treatment-of-non-small-cell-lung-carcinoma
#10
REVIEW
Venugopal Vinod Prabhu, Niranjali Devaraj
Lung cancer is responsible for 1.6 million deaths. Approximately 80%-85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach-surgery, chemotherapy, radiotherapy, and/or immunotherapy-is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations...
2017: Journal of Environmental Pathology, Toxicology and Oncology
https://www.readbyqxmd.com/read/29141962/personalised-medicine-for-nonsmall-cell-lung-cancer
#11
Céline Mascaux, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29125548/liquid-biopsy-and-therapeutic-targets-present-and-future-issues-in-thoracic-oncology
#12
REVIEW
Paul Hofman
The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue...
November 10, 2017: Cancers
https://www.readbyqxmd.com/read/29137182/current-and-prospective-protein-biomarkers-of-lung-cancer
#13
REVIEW
Tatiana N Zamay, Galina S Zamay, Olga S Kolovskaya, Ruslan A Zukov, Marina M Petrova, Ana Gargaun, Maxim V Berezovski, Anna S Kichkailo
Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream...
November 13, 2017: Cancers
https://www.readbyqxmd.com/read/29120087/histological-evolution-from-primary-lung-adenocarcinoma-harboring-egfr-mutation-to-high-grade-neuroendocrine-carcinoma
#14
Jikai Zhao, Jinchen Shao, Ruiying Zhao, Rong Li, Keke Yu, Lei Zhu, Jie Zhang
BACKGROUND: Although patients with EGFR mutated lung adenocarcinoma benefit greatly from tyrosine kinase inhibitors (TKIs), they inevitably develop acquired resistance after an average of 10-14 months of continuous treatment. METHODS: We retrospectively analyzed the clinical and histopathological data of eight patients with primary lung adenocarcinoma harboring EGFR mutations that transformed into high-grade neuroendocrine carcinoma after TKI therapy. Morphology scanning for neuroendocrine differentiation and immunohistochemistry for neuroendocrine markers CD56, chromogranin, and synaptophysin were performed on primary adenocarcinoma tissues and repeated biopsies...
November 9, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29114466/spread-through-air-spaces-stas-a-comprehensive-update
#15
REVIEW
Arne Warth
The new concept of spread through air spaces (STAS) was introduced for pulmonary adenocarcinomas (ADC) in the 2015 World Health Organization (WHO) classification for lung cancer. Yet available data demonstrate that STAS is of high prognostic impact and associated with specific clinic-pathological characteristics. This article provides a comprehensive overview on recent developments in this field.
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29114467/biology-of-invasive-mucinous-adenocarcinoma-of-the-lung
#16
REVIEW
Yoon Jin Cha, Hyo Sup Shim
Invasive mucinous adenocarcinoma (IMA) is a unique histologic subtype of lung adenocarcinoma. Recent studies document distinctive genetic alterations (e.g., NRG1 fusions) and a "mucinous gene signature" in IMAs, as well as differences in clinical responses to traditional chemotherapies in IMAs versus non-mucinous adenocarcinomas. Our understanding of the genetic and clinical characteristics of IMAs has expanded, confirming the uniqueness of IMAs. Accordingly, IMAs require different therapeutic approaches than do lung adenocarcinomas in general...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29114468/classification-of-pulmonary-neuroendocrine-tumors-new-insights
#17
REVIEW
Giuseppe Pelosi, Angelica Sonzogni, Sergio Harari, Adriana Albini, Enrica Bresaola, Caterina Marchiò, Federica Massa, Luisella Righi, Gaia Gatti, Nikolaos Papanikolaou, Namrata Vijayvergia, Fiorella Calabrese, Mauro Papotti
Neuroendocrine tumors of the lung (Lu-NETs) embrace a heterogeneous family of neoplasms classified into four histological variants, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). Defining criteria on resection specimens include mitotic count in 2 mm2 and the presence or absence of necrosis, alongside a constellation of cytological and histological traits including cell size and shape, nuclear features and overall architecture...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29114469/update-on-large-cell-neuroendocrine-carcinoma
#18
REVIEW
Kenzo Hiroshima, Mari Mino-Kenudson
High-grade neuroendocrine carcinomas of the lung are classified into two categories: large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). While typical cases of LCNEC are morphologically distinct from SCLC, the differentiation between LCNEC and SCLC can be challenging in some cases. In fact, there are borderline high-grade neuroendocrine carcinomas that morphologically fall between LCNEC and SCLC. Growing evidence suggests that LCNEC is a histologically and biologically heterogeneous group of tumors...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29114471/beyond-alk-and-ros1-ret-ntrk-egfr-and-braf-gene-rearrangements-in-non-small-cell-lung-cancer
#19
REVIEW
Anna F Farago, Christopher G Azzoli
The discovery of gene rearrangements involving the receptor tyrosine kinase genes ALK and ROS1 has revolutionized management of the subset of non-small cell lung cancers characterized by these alterations. The oncogenic fusion proteins expressed in these tumors drive cancer cell growth and survival, and targeted inhibition of this signaling can lead to dramatic and durable responses in patients. While the best characterized gene fusions in non-small cell lung cancer (NSCLC) involve ALK and ROS1, fusions involving other kinases including RET, NTRK, EGFR and BRAF are now established as additional targetable drivers...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29114472/molecular-diagnostics-of-lung-cancer-in-the-clinic
#20
REVIEW
Lynette Sholl
According to current practice guidelines, all patients with advanced non-small cell lung cancer (NSCLC) should undergo predictive biomarker testing. For squamous cell carcinoma patients, PD-L1 immunohistochemistry is indicated to select patients for immunotherapy in the first line. For lung adenocarcinoma, all patients with advanced disease should undergo testing for epidermal growth factor receptor (EGFR) mutations, ALK and ROS1 rearrangements, and PD-L1 expression to predict response to EGFR, ALK, or ROS1 targeted inhibitors or immunotherapy, respectively...
October 2017: Translational Lung Cancer Research
label_collection
label_collection
6334
1
2
2017-11-11 13:12:38
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"